After consecutive years of net losses, Pharming Group N.V. reversed its financial trajectory in 2025, achieving a positive net income of $2.54 million driven primarily by significant revenue growth in their flagship rare disease products RUCONEST® and Joenja®. This turnaround reflects increased physician adoption, patient transitions, and expanded geographic reach, particularly in the US market. Simultaneously, Pharming augmented its late-stage pipeline with the acquisition of napazimone (KL1333) for mitochondrial diseases, while regulatory milestones pave the way for further approvals in Europe and Japan. Despite ongoing risks related to regulatory processes and market competition, the company balances investment in commercialization and R&D alongside disciplined capital management.